GILEAD SCIENCES, INC.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
GILD$170.87+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended · Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | September 30, | |||
| (in millions, except per share amounts) | 2025 | 2024 | 2025 | 2024 |
| Revenues: | ||||
| Product sales | $7,345 | $7,515 | $21,013 | $21,074 |
| Royalty, contract and other revenues | 424 | 30 | 505 | 111 |
| Total revenues | 7,769 | 7,545 | 21,518 | 21,185 |
| Costs and expenses: | ||||
| Cost of goods sold | 1,569 | 1,574 | 4,610 | 4,670 |
| Research and development expenses | 1,346 | 1,395 | 4,215 | 4,266 |
| Acquired in-process research and development expenses | 170 | 505 | 485 | 4,674 |
| In-process research and development impairments | — | 1,750 | 190 | 4,180 |
| Selling, general and administrative expenses | 1,357 | 1,433 | 3,980 | 4,184 |
| Total costs and expenses | 4,442 | 6,657 | 13,480 | 21,975 |
| Operating income (loss) | 3,327 | 888 | 8,038 | (790) |
| Interest expense | 256 | 238 | 769 | 728 |
| Other (income) expense, net | (569) | (306) | (449) | (41) |
| Income (loss) before income taxes | 3,641 | 956 | 7,718 | (1,477) |
| Income tax expense (benefit) | 589 | (297) | 1,391 | (174) |
| Net income (loss) | 3,052 | 1,253 | 6,327 | (1,303) |
| Net income attributable to noncontrolling interest | — | — | — | — |
| Net income (loss) attributable to Gilead | $3,052 | $1,253 | $6,327 | $(1,303) |
| Basic earnings (loss) per share attributable to Gilead | $2.46 | $1.00 | $5.08 | $(1.04) |
| Diluted earnings (loss) per share attributable to Gilead | $2.43 | $1.00 | $5.04 | $(1.04) |
| Shares used in basic earnings (loss) per share attributable to Gilead calculation | 1,243 | 1,247 | 1,245 | 1,247 |
| Shares used in diluted earnings (loss) per share attributable to Gilead calculation | 1,254 | 1,254 | 1,256 | 1,247 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.